TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Variants in triggering receptor expressed on myeloid cells 2 (TREM2) confer high risk for Alzheimer’s disease (AD) and other neurodegenerative diseases. However, the cell types and mechanisms underlying TREM2’s involvement in neurodegeneration remain to be established. Here, we report that TREM2 is up-regulated on myeloid cells surrounding amyloid deposits in AD mouse models and human AD tissue. TREM2 was detected on CD45hiLy6C+ myeloid cells, but not on P2RY12+ parenchymal microglia. In AD mice deficient for TREM2, the CD45hiLy6C+ macrophages are virtually eliminated, resulting in reduced inflammation and ameliorated amyloid and tau pathologies. These data suggest a functionally important role for TREM2+ macrophages in AD pathogenesis and an unexpected, detrimental role of TREM2 in AD pathology. These findings have direct implications for future development of TREM2-targeted therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trem2, a myeloid protein involved in microglial survival and proliferation, regulates a checkpoint necessary for DAM and deletion of Trem2 prevents microglial accumulation around Aβ plaques and leads to additional neuritic damage [6, 14–17].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [14]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“TREM2 was recently demonstrated to be essential for promoting microglial cell association with plaques44–49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Although numerous studies have reported that TREM2 expression is upregulated in amyloid plaque-associated microglia in vivo (Frank et al., 2008; Jay et al., 2015), our research is the first to show that PU.1 knockdown abrogates this phenomenon in vitro.”
From PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease (2025) · cites this paper as Jay et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have all been shown to have opposing effects on amyloid and tau pathologies [49–51, 55–65].”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [59]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [16]
Experimental — accuracy not yet measured
34 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“5XFAD mice (The Jackson Laboratory B6SJL-Tg(APPSwFlLon,PSEN1*M146*l286V)) express mutant human APP(695) with Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations and human PSEN1 with M146L and L286V mutations under control of the Thy1 promoter (Oakley et al., 2006).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Notably, variants of the immune cell– specific triggering receptor expressed on myeloid cells 2 (TREM2) confer dramatically elevated risk for developing AD (R. Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 3×
“First, we found that TREM2+ cells in AD mouse models 2013; Butovsky et al., 2014), was expressed by parenchymal, nonplaque-associated cells in APPPS1;Trem2+/+ mice (Fig.”
BackgroundSelf-citationIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“TREM2, along with its obligate intracellular adaptor DAP12, was identified as a hub gene in systems biology analyses in AD (Forabosco et al., 2013; Zhang et al., 2013), highlighting the central importance of these myeloid cell signaling elements CORRESPONDENCE Bruce T.”
BackgroundThe microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“However, recent genome-wide association studies linked polymorphisms in inflammation-related genes to increased AD risk, supporting the conclusion that inflammation can be a causative factor in disease pathology (Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“The potential role of peripherally derived macrophages in AD has been controversial (Prinz and Priller, 2014), but it is well accepted that CD45hiLy6C+CCR2+ monocytes enter the central nervous system (CNS) and modulate pathology in other disease contexts (Mildner et al.”
BackgroundWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Cited by
Items 501–600 of 683
Lecordier, S., Menet, R., Allain, A., & ElAli, A. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231183742 · Cited by 14
Wickstead, E. S. (2023) · Biomedicines · doi:10.3390/biomedicines11082240 · Cited by 11
Glycolytic metabolism supports microglia training during age-related neurodegeneration
Camacho‐Morales, A. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00363-2 · Cited by 11
“In addition, TREM2 ablation in microglia decreases chemotaxis and chemoattraction [73] and blocks the response to inflammatory stimuli and around amyloid plaques [27, 74], due in part to Sall1 and TGFbr1 genomic upregulation [75].”
BackgroundInfluentialRecent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer’s Disease
Pradhan, L. K., Sahoo, P. K., Chauhan, S., & Das, S. K. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02009-7 · Cited by 13
“Furthermore, studies in the mice model of AD suggest that deficiency or haploinsufficiency of TREM2 alters microglial function (Wang et al. 2015; Ulrich et al. 2014; Meilandt et al. 2020; Jay et al. 2015).”
BackgroundTaxifolin for Cognitive Preservation in Patients with Mild Cognitive Impairment or Mild Dementia
Hattori, Y., Saitô, S., Nakaoku, Y., Ogata, S., Hattori, M., Nakatsuji, M., Nishimura, K., & Ihara, M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221293 · Cited by 14
“TREM2, a transmembrane protein expressed exclusively on microglia in the brain, may be implicated in the pathology of neuroinflammation and concomitant neurodegeneration such as AD and tauopathy, as shown in some in vivo studies [30, 31].”
BackgroundGandy, S., & Ehrlich, M. E. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02895-7 · Cited by 11
“Genetic deletion of Trem2 exerted different outcomes depending on the transgenic line, timing of the intervention and the age of the mouse [15].”
BackgroundInfluentialAssessing disease-modifying effects of norepinephrine in Down syndrome and Alzheimer’s disease
Ponnusamy, R., McNerney, M. W., Moghadam, S., & Salehi, A. (2017) · Brain Research · doi:10.1016/j.brainres.2017.09.035 · Cited by 11
Interferon-γ as a Potential Link between Diabetes Mellitus and Dementia
Cozachenco, D., Sellés, M. C., & Ribeiro, F. C. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.3046-18.2019 · Cited by 12
Katsumoto, A., Kokiko‐Cochran, O. N., Bemiller, S. M., Xu, G., Ransohoff, R. M., & Lamb, B. T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978423 · Cited by 12
“We also used a Trem2 mouse model (Trem2tm1(KOMP)Vlcg) as previously described (28).”
MethodSelf-citationTakeuchi, L. E., Kalia, L. V., & Simmons, C. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106864 · Cited by 13
“…these risk factors, the generation of such models remains of high importance to compliment work recently conducted in developing notable in vivo models including CD33 (Eskandari-Sedighi et al., 2024), TREM2 knock out (Jay et al., 2015) and TREM2 R47H (Tran et al., 2023; Ulland et al., 2017) models.”
Dongre, P., Ramesh, M., Govindaraju, T., & Inamdar, M. S. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03415-5 · Cited by 14
“While one report indicates that TREM2 knockout reduces inflammatory macrophages and ameliorates Aβ pathology [68] another demonstrates that TREM2 knockout reduces microglial activation and increases Aβ pathology [59].”
Ahmed, M. E., Selvakumar, G. P., Thangavel, R., Kempuraj, D., Raikwar, S. P., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09929-4 · Cited by 10
Nam, Y., Ji, Y., Shin, S. J., Park, H. H., Yeon, S.-H., Kim, S.-Y., Son, R. H., Jang, G. Y., Kim, H. D., & Moon, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117090 · Cited by 10
Headmasters: Microglial regulation of learning and memory in health and disease
Weinhard, L., d’Errico, P., & Tay, T. L. (2018) · AIMS molecular science · doi:10.3934/molsci.2018.1.63 · Cited by 12
“However in 4 months old APPPS1 mice, the absence of TREM2 reduced inflammation and mitigated amyloid and Tau pathologies [179].”
Dou, Z., Guo, Y., Liu, J., Li, N., Chai, B., Li, X., Fu, R., & Wang, X. (2016) · PubMed Central · Cited by 10
Balancing Microglial Density and Activation in Central Nervous System Development and Disease
Wang, S., Pan, L., Sun, C., Ma, C., & Pan, H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050344 · Cited by 12
“…by microglial NLRP3 activation TREM2 signaling is regarded to promote microglial proliferation, cytokine secretion, and phagocytosis, regulating microglial survival and metabolism [101–103]. facilitate tau release tau, creating a self-perpetuating degenerative cycle [68,112–117] Deletion of”
Singhaarachchi, P. H., Antal, P., Calon, F., Culmsee, C., Delpech, J.-C., Feldotto, M., Geertsema, J., Hoeksema, E. E., Kőrösi, A., Layé, S., et al. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102821 · Cited by 13
Savonenko, A. V., Wong, P. C., & Li, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00022-8 · Cited by 9
Schwarz, H., Bässler, S., Balta, D., Socher, E., Zunke, F., & Arnold, P. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113977 · Cited by 8
García‐Alberca, J. M., de Rojas, I., Sánchez‐Mejías, E., Garrido-Martín, D., Gonzalez-Palma, L., Jiménez, S., Pino‐Ángeles, A., Cruz-Gamero, J. M., Mendoza, S., Alarcón‐Martín, E., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231150 · Cited by 9
Que, X., Zhang, T., Liu, X. Y., Yin, Y., Xia, X., Gong, P., Song, W., Qin, Q., Xu, Q., & Tang, Y. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102732 · Cited by 8
“TREM2 also promotes the clearance of A β plaques and tau protein aggregates, potentially influencing the pathological processes of AD (Jay et al., 2015; Ulrich et al., 2014).”
Ruan, E., Lin, J., Zhao, C., Sheng, Q., Chen, L., He, J., Duan, X., Qin, Y., Xing, T., Yang, S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci178349 · Cited by 8
Sterile innate immune mechanisms in neurodegenerative diseases
Ealy, A., Serapiglia, A. M., & Panicker, N. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111039 · Cited by 8
Neuroimmune Dysregulation and AI-Driven Therapeutic Strategies in Alzheimer’s Disease
Ghosh, S., Bhaskar, R., Singh, K. K., Sharma, S., Yarlagadda, B., Sinha, J. K., & Han, S. S. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01651-0 · Cited by 11
“…or loss of TREM2 impair acti - vated microglial function, diminishing clearance functions and metabolic fitness, thereby increasing amyloid seed - ing and exacerbating neuritic pathology in vivo (Jay et al. 2015; Wang et al. 2015; Mazaheri et al. 2017; Ulland et al. 2017; Parhizkar et al. 2019).”
Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F., Sun, G., Croft, N. P., Rossello, F. J., Simmons, R., Buckberry, S., Landin, D. V., et al. (2019) · doi:10.1101/639054 · Cited by 7
A systematic review of the role of TREM2 in Alzheimer’s disease
Yin, Y., Yang, H.-C., Li, R., Wu, G., Qin, Q., & Tang, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003000 · Cited by 11
Canet, G., Zussy, C., Vitalis, M., Morin, F., Chevallier, N., Hunt, H., Claeysen, S., Blaquière, M., Marchi, N., Planel, E., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17457 · Cited by 9
“TREM2 is essential for promoting microglial association with amyloid plaques and proliferation around them (Hansen et al., 2018; Jay et al., 2015; Wang et al., 2016).”
Afrakoti, L. G. M. P., Moghadam, S. D., & Hadinezhad, P. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251329188 · Cited by 16
Li, R., Zhang, J., Wu, J., Fan, J.-Q., & Lin, B. (2025) · Science Advances · doi:10.1126/sciadv.adw9299 · Cited by 12
“Critically, TREM2 loss- of-function variants are strongly linked to Alzheimer’s disease risk in human genetics, underscoring its nonredundant role in neuroprotection ( 13 , 14 ).”
Crosstalk between peripheral immunity and central nervous system in Alzheimer’s disease
Yang, H.-C., Qin, Q., Wang, M., Yin, Y., Li, R., & Tang, Y. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104743 · Cited by 12
Rajmani, R. S., & Surolia, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1347045 · Cited by 6
Npc1 deficiency impairs microglia function via TREM2-mTOR signaling in Niemann-Pick disease type C
Qiao, L., Han, X., Ru, D., Shang, X., Xiao, L., Gao, G., Zhang, C., Kang, J., Su, X., Liu, Y., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167478 · Cited by 9
Tian, M.-L., Ni, X.-N., Li, J., Tan, C., Cao, X., Tan, L., & Initiative, A. D. N. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00742 · Cited by 6
New “programmers” in tissue macrophage activation
Aschenbrenner, A. C., & Schultze, J. L. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-1943-9 · Cited by 7
Wei, Z., Pan, X., Cui, X., Zhang, J., Dai, X., Zeng, Y., & Chen, X. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1537388 · Cited by 7
Diurnal cortisol, neuroinflammation, and neuroimaging visual rating scales in memory clinic patients
Holleman, J., Daniilidou, M., Kåreholt, I., Aspö, M., Hagman, G., Udeh‐Momoh, C. T., Spulber, G., Kivipelto, M., Solomon, A., Matton, A., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.03.024 · Cited by 6
Unraveling the complexity of microglial responses in traumatic brain and spinal cord injury
Henry, R. J., & Loane, D. J. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19102-2.00015-6 · Cited by 7
Zhou, M., & Pang, X. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1571563 · Cited by 9
Tsui, J. S. M., Au, D. M., Uhm, H., Wong, W., Lo, R. M. N., Jiang, Y., Ip, F. C. F., Mok, K. Y., Wong, H. Y., Kwok, T. C. Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70586 · Cited by 8
Trem2 exacerbates ischemic brain injury through Gpnmb in a photothrombotic stroke model
Chen, X., Li, K., Liu, S., Zhao, J., Tiwari, S., Zeng, F., ZHAO, Y., Zhang, P., Tang, H., Zhao, H., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2523148123 · Cited by 7
Cheray, M., Stratoulias, V., Joseph, B., & Grabert, K. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00522 · Cited by 7
“, 2018), as well as reduced aggregation and proliferation around plaques (Jay et al., 2015; Wang et al., 2015).”
BackgroundThe engagement of microglia in tau-targeted immunotherapy in Alzheimer’s disease
Palova, D., Csokova, N. T., Markova, K., Kontseková, E., Kováčech, B., & Žilková, M. (2021) · General Physiology and Biophysics · doi:10.4149/gpb_2021029 · Cited by 7
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy
Levites, Y., Funk, C. C., Wang, X., Chakrabarty, P., McFarland, K. N., Bramblett, B., O’Neal, V., Liu, X., Ladd, T. B., Robinson, M., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00453-4 · Cited by 6
Cummings, J. L., & Fulkerson, N. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.008 · Cited by 7
“[18] Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, et al.”
BackgroundMicroglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States
Kuhn, M. K., & Proctor, E. A. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26723 · Cited by 5
“It was initially thought that TREM2 activity exacerbates AD pathology [86].”
Boreland, A. J., Abbo, Y., Li, X., Stillitano, A. C., Zhang, S., Duan, J., Pang, Z. P., & Hart, R. P. (2025) · Alcohol · doi:10.1016/j.alcohol.2025.10.006 · Cited by 10
Rikos, D., Siokas, V., Mentis, A. A., Aloizou, A., Liampas, I., Tsouris, Z., Peristeri, E., Stamati, P., Hadjigeorgiou, G. M., & Dardiotis, E. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2150844 · Cited by 15
“TREM2 has a greater affinity for amyloid oligomers than monomers [ 61 ] and is upregulated in microglia surrounding amyloid plaques [ 62 ], findings which support the notion that TREM2 helps slow the processes behind AD once these have begun, and not before their inception.”
BackgroundThe Amyloid-beta rich CNS environment alters myeloid cell functionality independent of their origin
Drost, N., Houtman, J., Cseresnyés, Z., Niesner, R. A., Rinnenthal, J.-L., Miller, K. R., Prokop, S., & Heppner, F. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-63989-3 · Cited by 5
Druggable targets for the immunopathy of Alzheimer's disease
Weaver, D. F. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00096f · Cited by 5
Multi-omics analyses reveal novel effects of PLCγ2 deficiency in the mouse brain
Hopp, S. C., Rogers, J. G., Smith, S., Campos, G., Miller, H., Barannikov, S., Kuri, E. G., Wang, H., Han, X., Bieniek, K. F., et al. (2023) · doi:10.1101/2023.12.06.570499 · Cited by 7
“The TREM2/PLCγ2 signaling axis has been proposed to regulate phagocytosis, secretion of cytokines and chemokines, cell survival and proliferation (14, 24, 25).”
BackgroundLipid metabolism in Alzheimer’s disease
Zhang, J., & Sima, J. (2024) · Aging Research · doi:10.26599/agr.2025.9340037 · Cited by 4
The Therapeutic Potential of ADSC-Secreted LEFTY2 in Treating Alzheimer’s Disease
Wuli, W., Yang, H., Chiou, T., Woon, P. Y., Xu, Y., Tjandra, C., Wijaya, I., Harn, H., & Lin, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073382 · Cited by 4
“TREM2, a receptor expressed on microglia, has been recognized for its protective role in AD, enhancing microglial activity, promoting the clearance of A β , and attenuating Tau pathology [27,28].”
Khaled, M., Al-Jamal, H., Tajer, L., & El-Mir, R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231432 · Cited by 4
Bibliometric Analysis of TREM2 (2001-2022): Trends, Hotspots and Prospects in Human Disease
Qian, M., Zhong, J., Lu, Z., Zhang, W., Weng, M., Zhang, K., & Jin, Y. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.96851 · Cited by 5
“Simultaneously, TREM2 has witnessed significant breakthroughs in various fields, including inflammation, aging, and neurodegenerative diseases [38-42].”
BackgroundWang, Y., Huang, L., Guo, H., Liu, M., Zhang, Y., Zhang, Z., Hao, Q., Tan, C., & Tan, L. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16273 · Cited by 6
“On the other hand, TREM 2 has been reported to exacerbate A β and tau pathologies in AD mice experiments (Jay et al., 2015); chronic microglial activation was related to the release of pro-inflammatory cytokines, which can induce AD pathology (Heneka, Carson, et al., 2015).”
Generation of an Inducible Destabilized‐Domain Cre Mouse Line to Target Disease Associated Microglia
Henningfield, C. M., Ngo, M., Murray, K. M., Kwang, N. E., Tsourmas, K. I., Neumann, J. C., Pashkutz, Z. A., Kawauchi, S., Swarup, V., Lane, T. E., et al. (2025) · Glia · doi:10.1002/glia.70004 · Cited by 4
“For example, TREM2 mediates the microglial response to plaques, as shown by its knockout in models of amyloidosis (Keren-Shaul et al. 2017; Jay et al. 2015; Wang et al. 2016), but loss of TREM2 function also causes perturbations in homeostatic microglial function leading to the neurodegenerative…”
Wang, M., Wei, T., Yu, C., Li, R., Yin, Y., Yang, H.-C., Di, R., Xia, X., Qin, Q., & Tang, Y. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03840-8 · Cited by 6
“1) [14, 15].”
Maguire, E., Menzies, G. E., Phillips, T., Sasner, M., Williams, H. M., Czubala, M. A., Evans, N., Cope, E. L., Sims, R., Howell, G. R., et al. (2020) · doi:10.1101/2020.04.27.059600 · Cited by 4
Self-citationAndreo‐Lopez, J., Nuñez‐Diaz, C., Huynh, K. D., Nguyen, M. M. T., Cunha, C. D., Cantero‐Molina, F., Campos‐Moreno, C., Zimbone, S., Bellia, F., Giuffrida, M. L., et al. (2025) · Aging Cell · doi:10.1111/acel.70094 · Cited by 3
“…plaques, making them more diffuse and surrounded by more neuritic damage, suggesting that the microglial response to plaques is dependent on TREM2 expression (Jay et al. 2015; Puntambekar et al. 2022; Takahashi et al. 2005; Ulrich et al. 2014; Wang et al. 2015; Wang et al. 2016; Wood et al. 2022).”
Sex-Specific Molecular Architecture of Microglia-Mediated Neuronal Pruning Across the Human Lifespan
Sanfilippo, C., Castrogiovanni, P., Imbesi, R., Vecchio, M. M., & Rosa, M. D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05547-4 · Cited by 3
“The TREM2 pathway of signaling controls different characteristics of microglial activity, including damage-associated molecular process response, cellular debris scavenging, and pro-inflammatory cytokine production [6].”
Chen, Y., Zeng, Z., Wei, Z., Zhan, Y., Wu, L., Zhu, X., & Li, M. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00377-1 · Cited by 3
Pathological Roles of INPP5D in Alzheimer’s Disease
Chu, Y. N., Akahori, A., Takatori, S., & Tomita, T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-31978-5_30 · Cited by 4
Yuan, Q., Liu, X., Zhang, Y., Xian, Y., Zou, J., Zhang, X., Huang, P., Song, Y., & Lin, Z. (2021) · Molecules · doi:10.3390/molecules26092685 · Cited by 3
“Reactive gliosis is one of the pathological hallmarks of AD [6,14].”
BackgroundLeavy, O. (2015) · Nature reviews. Immunology · doi:10.1038/nri3842 · Cited by 3
Design of Novel PPAR Agonist for Neurodegenerative Disease
Steinke, I., & Amin, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-78315-0_10 · Cited by 4
How Many Alzheimer–Perusini’s Atypical Forms Do We Still Have to Discover?
Donato, L., Mordà, D., Scimone, C., Alibrandi, S., D’Angelo, R., & Sidoti, A. (2023) · Biomedicines · doi:10.3390/biomedicines11072035 · Cited by 3
Glia in Neurodegenerative Disease
Crowley, G., Attwell, D., Phatnani, H. P., Sontheimer, H. W., & Hong, S. Y. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041375 · Cited by 3
Chiba, T., Hattori, Y., Asakura, K., Sano, Y., Saitô, S., Minami, M., Yamamoto, H., & Ihara, M. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1686381 · Cited by 2
Xing, J. F., Mu, K., Xue, Y., Yang, X., Zhang, D., Gao, W., Zhang, T., Yang, S., Wang, R., Zhang, W., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843978 · Cited by 2
Immune Sensors, Regulators, and Effectors of Brain Health
Acıoğlu, Ç., & Elkabes, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_3 · Cited by 2
Beyond plaques and tangles: The role of immune cell dysfunction in Alzheimer's disease
Hussain, N., Khan, M. M., Sharma, A., Singh, R. K., & Khan, R. H. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.105947 · Cited by 2
Liu, C., Wang, X., Xu, W., Yu, S., Zhang, Y., Xu, Q., & Tan, X. (2025) · Pharmaceuticals · doi:10.3390/ph18070977 · Cited by 2
“Notably, TREM2 expression is upregulated around A β plaques, suggesting a compensatory neuroprotective response during AD pathogenesis [29,30].”
Is Alzheimer's Associated Amyloid Beta an Innate Immune Protein
Kandel, R., White, M. R., Hseih, I.-N., & Hartshorn, K. L. (2016) · InTech eBooks · doi:10.5772/63021 · Cited by 1
Neuroinflammation in Age-Related Neurodegenerative Diseases
MacPherson, K. P., Rodrigues, M. E. D. S., Cintron, A. F., & Tansey, M. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00016-x · Cited by 3
Blank-Stein, N., Mayer, M., & Mass, E. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.001 · Cited by 4
Reddy, J. S., Wang, X., Allen, M., Carrasquillo, M. M., Biernacka, J. M., Jenkins, G. D., Coombes, B. J., Belbin, O., Golde, T. E., Ertekin‐Taner, N., et al. (2022) · medRxiv · doi:10.1101/2022.07.12.22277557 · Cited by 3
“microglial cells [19], and TREM2 expression is increased both in the brains of AD patients [2023] and in mouse models of amyloid and tau deposition [24-28].”
BackgroundPark, T., Chang, L., Chung, S. W., Lee, S., Bae, S., Condello, C., Kim, Y. H., Lee, J., Kim, H.-J., Kwon, H.-K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.13.612389 · Cited by 2
“Given that Aβ plaques tend to suppress P2RY12 expression ( 20, 60 ), impair microglial function ( 12 ), and directly affect neuronal activity ( 15 ), it is essential to delineate whether these effects are primarily driven by IL-10/TGF-β signaling or occur secondary to enhanced plaque clearance.”
Genetically Engineered Mouse Models for Alzheimer Disease and Frontotemporal Dementia
Chiu, Y., Xia, S., Qiao, H., & Zhao, Z. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.11.006 · Cited by 6
Carpanini, S. M., Bradford, B. M., Alfieri, A., Piccardo, P., Monzón‐Sandoval, J., Brown, D., Boyle, A., Pokrovskaya, A., Mabbott, N. A., Manson, J. C., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1525017 · Cited by 2
Myers, S. J., Medapati, M. R., Allman, B. L., Pasternak, S., Whitehead, S. N., & Roseborough, A. D. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101261 · Cited by 1
“…surface receptor that functions via its interaction with the DAP12 protein to initiate pathways that promote phagocytosis, survival, chemotaxis, inflammatory responses, and proliferation (Keren-Shaul et al., 2017; Wang et al., 2020; Hsieh et al., 2009; Zheng et al., 2017; Mazaheri et al.,…”
Song, M., Liu, R., Zhang, L., Liu, C., Song, F., & Zhao, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117551 · Cited by 1
Harnessing the microbiome to regulate myeloid TREM2 expression and innate immune responses
Mihori, S., Nichols, F. C., Jellison, E. R., Blesso, C. N., Graziano, V. R., Rathinam, V. A. K., & Clark, R. B. (2026) · ImmunoHorizons · doi:10.1093/immhor/vlaf073 · Cited by 1
Hirota, Y., Yamamoto, J., Takatori, S., Sakakibara, Y., Takei, K., 佐治多美子, Sekiya, M., Tomita, T., & Iijima, K. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00032-1 · Cited by 1
“…TREM2-TYROBP/DAP12 signaling has been reported to control the dynamics of peripheral monocytes and macrophages that infiltrate the brain [134–136], we did not examine the role of peripheral myeloid cells in the maintenance of axonal integrity, which hinders fully disentangling…”
Multiscale Approximations to Understand the Complex Role of Microglia in Alzheimer's Disease
Martínez-Tazo, P., Mejias‐Ortega, M., López-López, V., Bhojwani-Cabrera, A. M., Saxton, E., Canals, S., Hardingham, G. E., Gutiérrez, A., López‐Atalaya, J. P., & Santis, S. D. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70536 · Cited by 2
“…of genetic variants, such as R47H, disrupts this coordinated response, resulting in decreased microglial clustering, impaired plaque compaction, and the emergence of more filamentous and neurotoxic plaques (Jay et al. 2015, 2017; Cheng-Hathaway et al. 2018; Wood et al. 2022; Liu et al. 2023).”
Novel Somatostatin Receptor Subtype‐4 Agonist Mitigates Microglia Inflammatory Activation
Silwal, A., Mobayen, S., Crider, A. M., Neumann, W. L., House, A., Umbaugh, D. S., Bhandari, S., Sandoval, K. E., & WITT, K. A. (2019) · The FASEB Journal · doi:10.1096/fasebj.2019.33.1_supplement.501.3 · Cited by 1
Os impactos da neuroinflamação na Doença de Alzheimer
Resende, A. C. G., & Brand, C. (2023) · Clinical & Biomedical Research · doi:10.22491/2357-9730.120200 · Cited by 27
Chettupalli, A. K., Gupta, N., Bukke, S. P. N., Singh, M. P., & Mandal, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118803 · Cited by 1
Microglial Biology and Physiology
Butovsky, O., Madore, C., & Weiner, H. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_13 · Cited by 2
Self-citationImportance of Microglial Cytoskeleton and the Actin-interacting Proteins in Alzheimer's Disease
Choi, G.-E. (2020) · Biomedical Science Letters · doi:10.15616/bsl.2020.26.1.1 · Cited by 1
Inflammation and insulin resistance in Alzheimer’s disease
Nash, Y., & Frenkel, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00025-6 · Cited by 1
Kotredes, K. P., Oblak, A. L., Pandey, R. S., Lin, P. B., Garceau, D. T., Williams, H. M., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-580913/v1 · Cited by 1
Self-citationCarbajosa, G., Malki, K., Lawless, N., Wang, H., Ryder, J. W., Wozniak, E., Wood, K., Mein, C. A., Hodgkinson, A., Dobson, R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.16.452732 · Cited by 1
“Behavioural data to support these findings is however currently lacking and some studies have reported lower plaque load in the absence of TREM2 (Jay et al., 2015; Krasemann et al., 2017).”
BackgroundResultLoss of TREM2 exacerbates parenchymal amyloid pathology but diminishes CAA in Tg-SwDI micePreprint
Zhong, R., Xu, Y., Williams, J. W., & Li, L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.04.565659 · Cited by 1
Gutierrez-Kuri, E., Marie Garcia-Rogers, J. L., Perez, J., Smith, S., Kenwood, M. R., Archuleta, K. S., Xiao, Y., Campos, G., Barannikov, S., Wang, H., et al. (2026) · doi:10.64898/2026.07.13.738356
Wolozin, B. L., & Ikezu, T. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.012
“Loss of function mutations of TREM2 or TYROBP are linked to highly inflammatory Nasu-Hakola disease in human, whereas disruption of TREM2 in amyloid precursor protein (APP)-overexpressing mice, a model of AD, results in reduced inflammation and Aβ accumulation in mouse brain (Jay et al., 2015).”
BackgroundMicroglia: A Double-Sided Sword in Stroke
Shi, H., Xu, M., Shi, Y., Gao, Y., Chen, J., & Hu, X. (2016) · Springer series in translational stroke research · doi:10.1007/978-3-319-32337-4_7
Microglia phenotypes in aging-associated diseases
Yin, Z. (2017) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Phillips, E. C. (2017) · Research Portal (King's College London)
Boza‐Serrano, A., Ruiz, R., Sanchez-Varo, R. M., Yang, Y., García‐Revilla, J., Jiménez-Ferrer, I., Paulus, A., Wennström, M., Vilalta, A., Allendorf, D. H., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/477927
Fat‐fated microglial dysfunction
Silvin, A., & Ginhoux, F. (2018) · The EMBO Journal · doi:10.15252/embj.2018101176
“Biochem Biophys Res Commun 343: 229 – 238 Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT (2015) TREM2 deficiency eliminates TREM2 inflamma…”
Metadata
- Authors
- Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., Cotleur, A. C., Butovsky, O., Bekris, L., Staugaitis, S. M., Leverenz, J. B., Pimplikar, S. W., Landreth, G. E., Howell, G. R., Ransohoff, R. M., & Lamb, B. T.
- Affiliations
- Cleveland Clinic (US)
- The Lerner Research Institute 1 and 2
- Jackson Laboratory (US)
- Case Western Reserve University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Lamb, Bruce T.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-03-02
- Volume
- 212
- Issue
- 3
- Pages
- 287-295
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4354365
- OpenAlex
- W2155344647
- Cited by
- 682
- References
- 33
- Citations by year
- 2026: 27 · 2025: 56 · 2024: 46 · 2023: 56 · 2022: 74 · 2021: 62 · 2020: 70 · 2019: 59 · 2018: 65 · 2017: 67 · 2016: 54 · 2015: 45
- FWCI
- 41.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000439)
- National Institute on Aging (R01AG023012, AG023012, F31AG048704)
- National Institute of General Medical Sciences (T32GM007250)
- National Institute of Neurological Disorders and Stroke (NS047804, T32NS067431, NS087298, R01NS088137, T32NS077888)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- TREM2, Alzheimer's disease, inflammatory macrophages, microglia, amyloid deposits, tau pathology, neuroinflammation, amyloidosis
- MeSH terms
- Age Factors, Aged, Alzheimer Disease, Animals, Disease Models, Animal, Female, Hippocampus, Humans, Macrophages, Male, Membrane Glycoproteins, Mice, Transgenic, Receptors, Immunologic, Up-Regulation, Amyloid beta-Peptides, tau Proteins, Leukocyte Common Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.